The Changing Epidemiology of Oropharyngeal Candidiasis in Patients with HIV/AIDS in the Era of Antiretroviral Therapy

Table 1

Patient demographics of 215 subjects by colonization status.

	Colonized
	Yes (𝑁=176)	No (𝑁=39)	𝑃-value
Age, mean (SD)	42.7 (8.9)	42.3 (8.5)	0.779^1
Male, 𝑛 (%)	157 (89.7)	34 (85)	0.393^2
White, 𝑛 (%)	54 (30.9)	7 (17.5)	0.134^3
Non-Hispanic, 𝑛 (%)	82 (46.9)	11 (27.5)	0.026^2
Years since diagnosis of HIV/AIDS, mean (SD)	8.4 (6.9)	6.4 (6.5)	0.086^4
Diabetic, 𝑛 (%)	15 (8.5)	2 (5)	0.745^3
History of Smoking, 𝑛 (%)	127 (72.1)	24 (60)	0.117^2
Uses dentures, 𝑛 (%)	42 (23.8)	3 (7.5)	0.018^3
Thrush present, 𝑛 (%)	59 (33.5)	0 (0)	<0.001^3
History of esophageal Candida, 𝑛 (%)	8 (4.5)	3 (7.5)	0.433^3
Decreased susceptibility to fluconazole, 𝑛 (%)	16 (9.1)	0 (0)	0.047^2
On ART therapy, 𝑛 (%)	117 (66.4)	31 (79.5)	0.145^2
History of antifungal use, 𝑛 (%)	59 (33.5)	20 (50)	0.054^2
CD4 count, mean (SD)	102.8 (80.3)	84.9 (67.8)	0.283^4
Viral load, mean (SD)	607142.5 (3442957.1)	103189.7 (161265.9)	0.588^4

¹𝐹 test.
²Pearson's 𝜒² test.
³Fisher's exact test.
⁴Kruskal-Wallis test.